Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AD-208 vs Avodart in Healthy Males
NCT04214808Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-208 in androgenetic alopecia (AGA) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the curve in time plot (AUCt) and Peak Plasma Concentration. Started Jan 2020; status: completed.
02
Drugs
AD-208
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04214808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214808.